The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Our Research Approach
- Genetic Therapies
- Clinical Trials
- Get Involved
- Our Advocacy Work
- North American CF Conference
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Care Centers
- Patient Assistance
- Infection Prevention and Control
- Patient Registry
- Coronavirus (COVID-19)
- Lung Transplantation
- In the Spotlight
- Diversity, Equity, and Inclusion
- Intro to CF
- Adult Care
- Clinician Resources
- Great Strides
- In Memoriam
- Researcher Resources
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
- (-) Health Care Reform
Un diagnóstico de fibrosis quística no debe descalificar a una persona para recibir atención que pueda salvarle la vida.
On Friday, a federal judge issued a decision in Texas v. United States, finding the Affordable Care Act to be unconstitutional. This decision could ultimately leave people with pre-existing conditions, like cystic fibrosis, without patient protections while also jeopardizing access to adequate, affordable health care coverage.
President Donald Trump signed an executive order on health care that could weaken patient protections. He also announced a plan to stop paying cost-sharing reduction (CSR) subsidies to health insurance companies. Both decisions could negatively affect people with cystic fibrosis.
The Cystic Fibrosis Foundation has joined 11 other patient groups in filing an amicus brief to challenge the short-term, limited-duration health insurance rule, which threatens access to adequate, affordable coverage for people with cystic fibrosis.
Responding to the U.S. Department of Health and Human Services final rule on short-term, limited-duration insurance plans, the Cystic Fibrosis Foundation joined 26 other nonpartisan patient and consumer groups to voice concern that these plans will split the market and jeopardize access to affordable, adequate health care for people living with pre-existing conditions.
Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
The Cystic Fibrosis Foundation joined 28 patient and consumer organizations in responding to new Centers for Medicare and Medicaid Services (CMS) guidance issued by the administration that undermines patient protections granted by the Affordable Care Act.
As the Senate considers adding repeal of the Affordable Care Act's (ACA) individual mandate to its tax reform package, a group of 16 nonpartisan patient and consumer groups issued a statement on last week's Congressional Budget Office (CBO) report.
A nonpartisan group of 18 patient, provider, and consumer groups renewed calls for Congress to act on the Bipartisan Health Care Stabilization Act of 2017 in light of Wednesday's Congressional Budget Office (CBO) report.